KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrana Health (ASTH) Asset Writedowns and Impairment (2016 - 2019)

Astrana Health's Asset Writedowns and Impairment history spans 7 years, with the latest figure at -$3.4 million for Q4 2019.

  • For Q4 2019, Asset Writedowns and Impairment fell 188.34% year-over-year to -$3.4 million; the TTM value through Sep 2020 reached -$3.4 million, down 237.75%, while the annual FY2023 figure was $422000.0, N/A changed from the prior year.
  • Asset Writedowns and Impairment for Q4 2019 was -$3.4 million at Astrana Health, down from -$2.3 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $3.8 million in Q4 2018 and bottomed at -$3.4 million in Q4 2019.
  • The 5-year median for Asset Writedowns and Impairment is $143500.0 (2015), against an average of $12066.6.
  • The largest YoY upside for Asset Writedowns and Impairment was 284.86% in 2019 against a maximum downside of 188.34% in 2019.
  • A 5-year view of Asset Writedowns and Impairment shows it stood at $126367.0 in 2015, then increased by 27.12% to $160633.0 in 2016, then crashed by 48.08% to $83395.0 in 2017, then soared by 4456.63% to $3.8 million in 2018, then tumbled by 188.34% to -$3.4 million in 2019.
  • Per Business Quant, the three most recent readings for ASTH's Asset Writedowns and Impairment are -$3.4 million (Q4 2019), -$2.3 million (Q2 2019), and $951000.0 (Q1 2019).